Meyka AI API is live for developers.Start building.
Advertisement
Akero Therapeutics, Inc.

Akero Therapeutics, Inc. (AKRO) Stock Overview

Explore Akero Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

AKRO●NASDAQ
HealthcareBiotechnology
$54.65
$0.00(0.00%)
U.S. Market opens in 64h 23m
Advertisement

Akero Therapeutics, Inc. (AKRO)

Meyka AI Score

Z

Key Financials

Market Cap4.5B
P/E Ratio-15.31
EPS (TTM)$-3.75
ROE-0.31%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

AKRO Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Akero Therapeutics, Inc. (AKRO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of N/A.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -15.31 and a market capitalization of 4.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
17.55%
6-Month Change
8.50%
Year-to-Date (YTD) Change
N/A
1-Year Change
108.91%
3-Year Change
23.95%
5-Year Change
89.17%
All-Time (Max) Change
198.31%

Contact Information

https://www.akerotx.com
650 487 6488
601 Gateway Boulevard, South San Francisco, CA, 94080

Company Facts

690 Employees
IPO DateJun 20, 2019
CountryUS

Frequently Asked Questions